New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2OP4exg
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2OP4exg